Clinical Scorecard: Evaluating the connection between cardiometabolic disorders and the likelihood of aggressive prostate cancer: a systematic review and meta-analysis

At a Glance

Key Highlights

• Prostate cancer is the most common malignancy among US men, with increasing incidence and significant mortality.
• Cardiometabolic diseases are highly prevalent and may contribute to the risk and aggressiveness of prostate cancer.
• Black American men experience higher prostate cancer incidence and mortality, alongside higher obesity rates, highlighting health disparities.

Guideline-Based Recommendations

Diagnosis

• Use BMI ≥30 kg/m2 and waist circumference >102 cm in men to assess obesity and central adiposity.
• Diagnose type 2 diabetes with fasting glucose ≥126 mg/dL or HbA1c ≥6.5%.
• Identify dyslipidemia by lipid profiles: low HDL (<40 mg/dL), high LDL (>130 mg/dL), high total cholesterol (>240 mg/dL), or high triglycerides (>200 mg/dL).
• Define hypertension as systolic BP >130 mmHg or diastolic BP >80 mmHg.
• Employ longitudinal cohort studies and validated criteria to assess aggressive prostate cancer progression.

Management

• Implement multi-modal treatments for aggressive prostate cancer including chemotherapy, androgen deprivation therapy, androgen receptor pathway inhibitors, and PSMA-targeted radioligand therapy.
• Address modifiable cardiometabolic risk factors through lifestyle interventions and medical management to potentially reduce prostate cancer progression risk.

Monitoring & Follow-up

• Regularly monitor prostate cancer progression stages (localized, regional, distant) and cardiometabolic disease markers.
• Screen high-risk populations, especially Black American men, for both prostate cancer and cardiometabolic conditions.

Risks

• Recognize that cardiometabolic diseases may increase risk for aggressive prostate cancer and poorer prognosis.
• Consider socioeconomic, healthcare access, environmental, and genetic factors contributing to disparities in prostate cancer outcomes.

Patient & Prescribing Data

Men diagnosed with or at risk for aggressive prostate cancer and cardiometabolic diseases, including high-risk racial groups.

Current treatments for aggressive prostate cancer remain incurable; managing cardiometabolic diseases may influence disease progression and improve outcomes.

Clinical Best Practices

• Incorporate comprehensive cardiometabolic risk assessment in prostate cancer patients.
• Use standardized definitions and diagnostic criteria for cardiometabolic diseases to guide risk stratification.
• Address health disparities by improving access to screening and care in vulnerable populations.
• Apply multi-disciplinary approaches combining oncology and metabolic disease management.
• Promote patient education on the link between cardiometabolic health and prostate cancer aggressiveness.

Related Resources & Content

• American Cancer Society Prostate Cancer Facts & Figures 2023
• CDC National Diabetes Statistics Report 2022
• PRISMA 2020 Statement
• STROBE Statement